Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics (2022)
Attributed to:
New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103856
PubMed Identifier: 35152152
Publication URI: http://europepmc.org/abstract/MED/35152152
Type: Journal Article/Review
Parent Publication: eBioMedicine